Review: Myeloid-derived suppressor cells (MDSCs) – Will it become a therapeutic target for Non- Hodgkin Lymphoma?

Non-Hodgkin’s lymphoma (NHL) is a varied set of lymphoproliferative disorders initiatingfrom B, T, or natural killer (NK) lymphocytes. Common treatments of NHL include chemotherapy regimens, radiotherapy, rituximab administration, transfusion of blood products and Peripheral blood stem cell transplantation. Recently, several targeted therapies have been approved or are in the later phase of clinical trials and molecular targeted therapy is considered as a key aspect of NHL. Successful treatment of lymphoma may result from the induction of specific antitumor immunity. Myeloid-derived suppressor cells (MDSC) are being investigated as a possible target in solid tumors and most of blood cancers to improve the effects of commonly used undergoing treatment. The anti-tumor immune response of a diseased person is inhibited by MDSC expansion, which restricts, cytokine secretion, T cell proliferation and the activation of regulatory T cells. In order to identify immunological therapeutic targets, it is critical to identify tumor-promoting factors. Since this environment is focus to low selective pressure for mutations, targeting the Tumor Microenvironment (TME) is a promising therapeutic option for Non-Hodgkin lymphoma. The features, distribution, roles, cellular reactions, and aiming MDSCs in Non-Hodgkin lymphoma are discussed in this review.